The randomized phase 3 PhALLCON trial was conducted in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The practice-changing efficacy results and safety data demonstrate a potential for a new standard-of-care therapy for frontline use in this patient population and improvements in long-term survival outcomes. touchONCOLOGY spoke with editorial board member and principle investigator of the trial, Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA), who summarized the key take-home messages.
The abstract (Abstract 398868) entitled ‘First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)’ was presented at the American Society of Clinical Oncology Annual Meeting, 2–6, June 2023.
Disclosures: Elias Jabbour has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of ASCO 2023
Access more content on haematological malignancies here
